Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Next Previous
Trial Profile

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Ibrutinib; Obinutuzumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 17 Jun 2021 Planned End Date changed from 31 Oct 2025 to 7 May 2028.
  • 17 Jun 2021 Planned primary completion date changed from 7 May 2021 to 7 May 2028.
  • 01 May 2021 Planned primary completion date changed from 31 Oct 2025 to 7 May 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top